Stock comparison
Halozyme Therapeutics
HALO$8.13BHealthcare Market cap, Sector
Jeena Sikho Lifecare Limited
JSLL.BO$69.36BHealthcare Market cap, Sector
Overall winner
Jeena Sikho Lifecare Limited
HALO 16 JSLL.BO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
HALO1wins
6winsJSLL.BO
78B
B84
90A
A87
64C
A92
62C
C66
42F
B75
81B
A91
83B
A95
Side-by-side metrics
| Metric | HALO | JSLL.BO |
|---|---|---|
| Market cap | $8.13B | $69.36B Winner |
| P/E (TTM) | Winner: 23.3x | 33.2x |
| EV/EBIT | Winner: 12.2x | 24.1x |
| ROIC (TTM) | 23.65% | 39.15% Winner |
| Gross margin | 76.93% | 88.58% Winner |
| Net margin | 23.13% | 27.68% Winner |
| Revenue CAGR 5y | 33.23% | 57.81% Winner |
| EPS CAGR 5y | -1.98% | 86.67% Winner |
| Debt / Equity | 9.8x | 0.3x Winner |
| Dividend yield | 0.0% | - |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- EV/EBIT12.2xvs 24.1x+49%
- P/E (TTM)23.3xvs 33.2x+30%
JSLL.BO leads on
- EPS CAGR 5y86.67%vs -1.98%+102%
- Debt / Equity0.3xvs 9.8x+97%
- Market cap$69.36Bvs $8.13B+88%
- Revenue CAGR 5y57.81%vs 33.23%+43%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.